摘要
目的系统评价Rg3联合化疗治疗中晚期非小细胞肺癌的临床疗效及安全性。方法在CNKI、CBM、VIP、万方数据库、the Cochrane Central Register of Controlled Trials(CENTRAL)、Pub Med、EMbase、the ISI Web of Knowledge Databases数据库中检索相关研究,日期截至2015年3月。纳入Rg3联合化疗治疗非小细胞肺癌(Rg3联合化疗组)及单纯化疗(单纯化疗组)的随机对照试验,并用Rev Man 5.2统计软件进行Meta分析。结果纳入14项研究,包括833例晚期非小细胞肺癌患者。Meta分析结果显示:Rg3联合化疗组的疗效与单纯化疗组比较,差异有高度统计学意义(OR=1.72,95%CI=1.27~2.33,P=0.0005),且与单纯化疗组比较,Rg3联合化疗组中1年生存率(OR=2.12,95%CI=1.29~3.50,P=0.003)、KPS评分(OR=4.99,95%CI=2.87~8.65,P<0.0001)提高。两组血清VEGF水平(MD=-39.61,95%CI=-61.11^-18.11,P=0.0003)、白细胞减少(OR=0.36,95%CI=0.22~0.59,P<0.0001)、血小板减少(OR=0.27,95%CI=0.11~0.68,P=0.005)及胃肠道不良反应(OR=0.41,95%CI=0.21~0.81,P=0.01)差异均有高度统计学意义,但两组肝肾功能不良反应发生率(OR=0.62,95%CI=0.18~2.12,P=0.44)差异无统计学意义。结论在治疗晚期非小细胞肺癌疗效方面,Rg3与化疗方案联合优于单纯化疗方案;在毒副作用方面,Rg3联合化疗治疗的骨髓抑制率、胃肠道不良反应发生率均明显低于单纯化疗者,但肝肾功能损害方面两者相当。
Objective To systematically evaluate the clinical efficacy and safety of the Rg3 combined with Chemothera- py in advanced non-small cell lung cancer. Methods Electronic databases including CNKI, CBM, VIP, Wanfang database, the Cochrane Central Register of Controlled Trials, PubMed, EMbase, the ISI Web of Knowledge Databases were searched, until March 2015. Randomized controlled trials （RCT） of the Rg3 combined chemotherapy （Rg3 com- bined chemotherapy group） and single chemotherapy （single chemotherapy group） in the treatment of non-small cell lung cancer were searched, and RevMan 5.2 software was used for Meta analysis. Results Fourteen RCTs were adopted, and 833 patients Of advanced non-small cell lung cancer were included. The result of the Meta-analysis exhibited that, response rate of Rg3 combined chemotherapy group compared and single chemotherapy group had statistically significant difference （0R=1.72, 95%CI=1.27-2.33, P=0.0005）, and Rg3 combined chemotherapy group could increase 1 year survival rate （OR=2.12, 95%CI=1.29-3.50, P=0.003） and KPS scale （OR=4.99, 95%CI =2.87-8.65, P 〈 0.0001）, com- pared with single chemotherapy group. Differences of two groups were statistically significant in serum VEGF levels （MD= -39.61, 95%CI=-61.11 - -18.11, P=0.0003）, leucopenia （OR=0.36, 95%CI=0.22-0.59, P 〈 0.0001）, thromboeytopenia （OR=0.27, 95%CI=0.11-0.68, P=0.005）, gastrointestinal adverse reaction （OR=0.41, 95%CI=0.21-0.81, P= 0.01）. But differences of incidence of adverse reactions in liver and kidney function was not statistically signifieant （OR=0.62, 95%CI=0.18-2.12, P=0.44）. Conclusion In the treatment of advanced non-small cell lung cancer, Rg3 combined with chemotherapy is better than chemotherapy alone. In terms of adverse reaction, bone marrow inhibition rate and incidence of gastrointestinal side effects of Rg3 combined with chemotherapy are significantly lower than those of chemotherapy alone, whereas adverse reactions to liver and kidney function are similar.
出处
《中国医药导报》
CAS
2015年第35期87-92,共6页
China Medical Herald
基金
湖北省武汉市科技计划项目(2013060602010269)
关键词
参一胶囊
RG3
96
非小细胞肺癌
Shenyi Capsules
Rg3
Chemotherapy
Non-small cell lung cancer
作者简介
方珊珊（1982-），女，武汉大学人民医院2012级生物医学工程专业在凑颐土目侈洼；研究方向：肿瘤分子靶向治疗。
【通讯作者】戈伟（1960-），男，博士，副教授，主任医师；研究方向：肿瘤分子靶向治疗。
